October 8, 2011 -- Guizhou Bailing Group Pharma will pay $4.4 million to acquire Zhengxin Pharma, a fellow ethnic-Miao TCM company; SciClone Pharma will repurchase up to $20 million of its stock over the next two years; GlaxoSmithKline is looking to complete “smaller” acquisitions in India in the $500 million to $2 billion range; India is worried China may grow to dominate India’s own pharma market, especially in APIs; and China’s government wants to curb overuse of antibiotics, which is causing a rise in drug-resistant infections. More details….
Stock Symbols: (SHE: 002424) (NSDQ: SCLN) (NYSE: GSK)
